醫藥股普遍隨A股續升 來凱(02105.HK)飆47% 藥明系續升10%-13%
恆指今早高開145點或0.9%報16,282,升幅曾擴至271點,高見16,408遇壓,最低見16,197,現報16,214,升77點或0.5%,50天線(16,272)得而復失;總成交額520億元。
A股醫藥生物及生物疫苗板塊今早續升。本港醫藥相關股普遍延續昨天升勢,來凱醫藥-B(02105.HK)高見4.93元,現報4.87元,飆47%,成交增至1,604萬股。
藥明合聯(02268.HK)高見19.88元,現報19.7元,續升逾13%。近日頻頻回購的藍籌藥明生物(02269.HK)高見20.8元,現報20.05元,續升10%;藥明康德(02359.HK)續升9.8%報53.8元。
信達生物(01801.HK)上季總產品收入年增逾65%,最高見36.15元,現報35.7元,續升8.2%。榮昌生物(09995.HK)高見19.78元,現報18.88元,續升6%。君實生物(01877.HK)高見13.32元,現報12.98元,續升4.7%。藍籌國藥(01099.HK)高見22.35元,現報22.2元,續升4.2%。
凱萊英(06821.HK)高見70元(暫受制20天線70.1元),現報68.15元,續升3.7%。康希諾生物(06185.HK)升破10天線,最高見17.38元,現報17.22元,續升3.9%。復星醫藥(02196.HK)重越10天線,最高見14.4元,現報14.3元,續升3.6%。
百濟神州(06160.HK)、諾誠健華(09969.HK)、雲頂新耀-B(01952.HK)、聯邦制藥(03933.HK)、康龍化成(03759.HK)及康寧傑瑞製藥-B(09966.HK)升3%-5%。
此外,京東健康(06618.HK)及阿里健康(00241.HK)均升破20天線,最高見29.9元及3.31元,現報29.25元及3.25元,續升3.4%及7.3%。平安好醫生(01833.HK)重越10天線,最高見12.18元,現報11.88元,續升3.3%。
然而,再鼎醫藥(09688.HK)失10天線(17.33元),現報16.44元,回吐7%。宜明昂科-B(01541.HK)續跌5.8%報21元。康諾亞-B(02162.HK)回吐3.3%報33.2元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.